Can you provide OEM or ODM services?

Yes, OEM and ODM services are available for this product.

What are the payment terms?

Payment terms include LC, T/T, and D/P.

What is the lead time for delivery?

The average lead time is 1-3 months for both peak and off-peak seasons.

Cefotaxime for Injection 1g with High Inspection

Name: Cefotaxime for Injection 1g with High Inspection
Brand: REYOUNG PHARMACEUTICAL CO., LTD.
SKU: 2020741522

Shandong, ChinaREYOUNG PHARMACEUTICAL CO., LTD.

US$0.17

100,000 vial

Sample price:US$2.00/vial.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

I.M/I.V Injection

Model NO.

Suitable for

Elderly, Children, Adult

State

Solid

Shape

Powder

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

Lu20160062

Drug Ad Approval No.

Lu20160062

Certificate

GMP, SGS, ISO

Transport

by Sea, by Air, by Land

Transport Pagage

Carton

Unit of Quantity

Vial

Transport Package

1/10/50 Vial/Box

Specification

Trademark

Reyoung

Origin

China

HS Code

3003909090

Production Capacity

5millions

Key features

Third-Generation Cephalosporin: Sterile powder for injection with excellent stability against beta-lactamase enzymes.

Broad-Spectrum Activity: Highly effective against Gram-negative bacteria, including Enterobacteriaceae and Neisseria species.

Neonatal Sepsis Treatment: Recommended first-line agent for empirical treatment of neonatal sepsis and meningitis.

Multiple Indications: Treats respiratory, urinary, intra-abdominal, skin, systemic infections, and meningitis.

GMP & ISO Certified: Manufactured by GMP, ISO9001, ISO14001 authenticated enterprise with international approvals.

OEM/ODM Services: Customization services available for packaging and product specifications.

Global Export Experience: Products exported to over 100 countries including EU, Brazil, and South Korea.

High Production Capacity: Annual capacity of 1.5 billion vials of powder for injection and 5 billion tablets.

Company profile

REYOUNG PHARMACEUTICAL CO., LTD.

Shandong, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service AvailableExport Year: 1997-01-01 CertifiedNearest Port: Qingdao PortAverage Response Time: >24h CertifiedTerms of Payment: LC, T/T, D/P

AI-Powered supplier vetting

SummaryREYOUNG PHARMACEUTICAL CO., LTD. is a China-based limited company established in 1998, with 4,950 employees and operations in Shandong. The supplier reports ISO 9001, ISO 14001, and OHSAS 18001 certifications, more than 10 production lines, 50 quality-control staff, and 370 years of combined R&D-engineer experience. Its stated manufacturing portfolio includes sterile raw materials, powders and liquids for injection, tablets, and capsules, with reported annual production above the stated threshold. The company identifies three factories, an extensive manufacturing area, international business since 1997, and export markets across South America, Africa, Southeast Asia, and the Middle East. Trade records show transactions involving India, Bolivia, and Vietnam, including cefotaxime-related products. Evidence is insufficient to assess after-sales service, financial credibility, innovation output, or customization capability. Customer-case evidence is limited to named buyers and trade records.

Supplier typeThe supplier is identified as a combined business entity and a limited company headquartered in Shandong, China. Its business scope is health and medicine, with products including sterile raw materials, injectable products, tablets, and capsules, supporting classification as a pharmaceutical manufacturer and distributor.

CertificationsThe supplier explicitly reports ISO 9001:2015, ISO 14001:2015, and OHSAS 18001:2007 certificates, and separately describes itself as GMP and ISO authenticated. These stated certifications provide direct evidence of formal quality, environmental, and occupational-health management systems.

Production capacityProduction capacity is supported by more than 10 production lines, three factories, a reported manufacturing area of 1,000,000 square meters, and stated annual output across small-volume injections, powder injections, tablets, and capsules. The supplier also reports annual production above the stated threshold, indicating substantial multi-form pharmaceutical manufacturing capability.

Client casesTrade records identify transactions involving STERILE INDIA PRIVATE LIMITED, HEREDIA ARACENA RENY EVELIN, and a Vietnam-related registration, with products including cefotaxime-related material and oral rehydration products. These records demonstrate some international commercial activity, but the evidence is limited and does not establish long-term customer performance or a broad verified customer portfolio.